Kisqali Alternatives
Drugs like Kisqali (ribociclib) — other oncology medications advertised on TV that may be alternatives. Informational only — not medical advice. Only your doctor can decide what's right for you.
Unverified catalogue summary (alternative grouping) for Kisqali in US; not checked against current local product information.
Keytruda
pembrolizumab · MSD International Business GmbH (manufactured for Merck Sharp & Dohme LLC)
Treats Multiple cancers
Unverified catalogue summary (alternative identity, manufacturer and indication) for Keytruda in US; not checked against current local product information.
Opdivo
nivolumab · Bristol-Myers Squibb
Treats Multiple cancers
Unverified catalogue summary (alternative identity, manufacturer and indication) for Opdivo in US; not checked against current local product information.
Xtandi
enzalutamide · Astellas Pharma US, Inc.
Treats Prostate cancer
Unverified catalogue summary (alternative identity, manufacturer and indication) for Xtandi in US; not checked against current local product information.
Verzenio
abemaciclib · Eli Lilly
Treats HR+/HER2- breast cancer
Unverified catalogue summary (alternative identity, manufacturer and indication) for Verzenio in US; not checked against current local product information.
Ibrance
palbociclib · Pfizer Laboratories (US labeler)
Treats HR-positive advanced or metastatic breast cancer, in specified HER2-negative and HER2-positive combination regimens
Unverified catalogue summary (alternative identity, manufacturer and indication) for Ibrance in US; not checked against current local product information.
Lynparza
olaparib · AstraZeneca
Treats Ovarian, breast, prostate, and pancreatic cancers
Unverified catalogue summary (alternative identity, manufacturer and indication) for Lynparza in US; not checked against current local product information.
Tagrisso
osimertinib · AstraZeneca
Treats EGFR mutation-positive non-small cell lung cancer
Unverified catalogue summary (alternative identity, manufacturer and indication) for Tagrisso in US; not checked against current local product information.
Calquence
acalabrutinib · AstraZeneca
Treats Chronic lymphocytic leukemia and mantle cell lymphoma
Unverified catalogue summary (alternative identity, manufacturer and indication) for Calquence in US; not checked against current local product information.
Imbruvica
ibrutinib · Pharmacyclics LLC / Janssen Biotech, Inc.
Treats Chronic lymphocytic leukemia and other blood cancers
Unverified catalogue summary (alternative identity, manufacturer and indication) for Imbruvica in US; not checked against current local product information.
Jakafi
ruxolitinib · Incyte
Treats Myelofibrosis and polycythemia vera
Unverified catalogue summary (alternative identity, manufacturer and indication) for Jakafi in US; not checked against current local product information.
Nubeqa
darolutamide · Orion Corporation / Bayer HealthCare Pharmaceuticals Inc.
Treats Prostate cancer
Unverified catalogue summary (alternative identity, manufacturer and indication) for Nubeqa in US; not checked against current local product information.
Erleada
apalutamide · Janssen
Treats Prostate cancer
Unverified catalogue summary (alternative identity, manufacturer and indication) for Erleada in US; not checked against current local product information.
Sources and editorial standards
Product-label references, not clinical verification. Medicine identification—not prescribing guidance. This page does not provide a complete safety or dosing reference. Check the official label for your country and exact product, and consult your pharmacist or prescriber before starting, stopping or changing treatment. Missing information does not mean a medicine is safe for you. Reference formulation scope (not dosing instructions): KISQALI oral film-coated ribociclib tablets, 200 mg (as ribociclib succinate; sections 3, 11). Not a separate KISQALI FEMARA co-pack.
Unresolved / not established by these sources:
- Clinical summaries, safety tiers and dosing guidance are withheld while their review remains unfinished.
- A linked document may have been superseded. Confirm country, product, formulation and latest revision with the regulator or pharmacist.
- US label reference: Kisqali — current sponsor US prescribing information (DailyMed SPL read 2026-10-01)
Manufacturer label · Reference scope: Reference link only. Verify the exact formulation and current revision; this does not certify a clinical summary.
Lookup resources (not product-specific citations; confirm formulation and country before use):
- DailyMed current labels for Kisqali
- DailyMed current labels for Keytruda
- DailyMed current labels for Opdivo
- DailyMed current labels for Xtandi
- DailyMed current labels for Verzenio
- DailyMed current labels for Ibrance
- DailyMed current labels for Lynparza
- DailyMed current labels for Tagrisso
- DailyMed current labels for Calquence
- DailyMed current labels for Imbruvica
- DailyMed current labels for Jakafi
- DailyMed current labels for Nubeqa
- DailyMed current labels for Erleada
- FDA drug approvals and databases
- How TVPills researches and reviews content
Frequently asked questions
What drugs are similar to Kisqali?
Unverified catalogue grouping, not a clinically established substitute or a checked local indication. Drugs like Kisqali include other oncology medications advertised on TV such as Keytruda, Opdivo, Xtandi and more. This is an editorial catalogue grouping, not a verified comparison of indications, safety or suitable substitutes. Ask your prescriber about treatment choices.
What can I take instead of Kisqali?
Unverified catalogue grouping, not a clinically established substitute or a checked local indication. Other oncology medications advertised on TV include Keytruda, Opdivo, Xtandi and others. The right alternative depends on your diagnosis, medical history and insurance — only your doctor can recommend a substitute for Kisqali. This page is informational only.
Is there a generic version of Kisqali?
Unverified catalogue grouping, not a clinically established substitute or a checked local indication. Kisqali is sold as ribociclib. Whether a lower-cost generic is available depends on patent status — ask your pharmacist, and see the cost & savings page for ways to pay less.
Are these alternatives the same as Kisqali?
Unverified catalogue grouping, not a clinically established substitute or a checked local indication. This catalogue grouping does not establish therapeutic equivalence, shared approved indications or suitability as a substitute. Do not switch medicines based on it; consult your prescriber.